Brief Prehabilitation Reduced Complications Prior to Gastrectomy - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Brief Prehabilitation Reduced Complications Prior to Gastrectomy

Researchers evaluate a supervised, home-based program combining exercise, nutrition, and psychological support before surgery

  • By

  • Kathryn Wighton

  • April 7, 2026

  • 3 min

Share

Objective:

To evaluate the impact of a supervised prehabilitation program on postoperative complications in older patients with frailty undergoing radical gastrectomy.

Approach:
    Key Findings:
    • 30-day postoperative complications were reduced in the prehabilitation group (17%) compared to standard care (29%).
    • Minor complications occurred in 11% of the prehabilitation group vs 20% in standard care.
    • Medical complications were 8% in the prehabilitation group vs 17% in standard care.
    • Improved postoperative recovery metrics: ICU admission (23% vs 33%), shorter mechanical ventilation, and shorter hospital stays (median 6 vs 8 days).
    • Functional capacity improved with a mean increase of 24 m in the 6-minute walk test in the prehabilitation group.
    • Biomarker improvements included decreased C-reactive protein and neutrophil-to-lymphocyte ratio.
    • Lower preoperative anemia rates in the prehabilitation group (19% vs 33%).
    Interpretation:

    Integrating a supervised, home-based, multimodal prehabilitation program with ERAS care may reduce surgical stress, enhance physiological reserves, and promote recovery in frail older patients.

    Limitations:
    • Inability to perform double-blinding.
    • Variability in frailty assessment tools.
    • Lack of survival data.
    Conclusion:

    The study suggests that prehabilitation can significantly reduce complications and improve recovery in frail older patients undergoing gastrectomy.

    Sources:

Original Source(s)

Brief Prehabilitation Reduced Complications Prior to Gastrectomy

  • by Kathryn Wighton

  • April 7, 2026

Related Content

Prehabilitation Program May Benefit Patients Undergoing CRC Surgery

Structured implementation increased participation and improved preoperative fitness, while postoperative complication and mortality rates remained similar across groups.

FDA expands gastroesophageal cancer options

Phase 3 findings showed longer median progression-free survival with zanidatamab-containing regimens vs trastuzumab plus chemotherapy.

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.